Sanofi Pasteur's Fluzone Quadrivalent helps protect adults and children as young as six months old against influenza B strain. The treatment is the newest addition to the company's "Fluzone" line of influenza vaccines.
There may be a cost savings for hospitals using Surfaxin, due to the reduced rate of reintubation among preterm infants, according to manufacturer Discovery Labs.
Three group purchasing agreements with Kimberly-Clark will provide specially negotiated pricing and terms for nearly 100,000 hospitals and care sites within the Premier Healthcare Alliance network.
The new noninvasive monitoring device, developed in conjunction with Mayo Clinic, remotely detects and monitors non-lethal cardiac arrhythmias while allowing patients freedom and mobility.
The Lung Volume Reduction Coil, created by PneumRx, is designed to improve lung function, exercise capacity and quality of life for people with advanced emphysema.
GlaxoSmithKline and Theravance Inc’s BREO ELLIPTA, an inhaled long-term, once-daily treatment for airflow obstruction in COPD patients, has received FDA approval.